BI

Bioqual IncOOTC BIOQ Stock Report

Last reporting period 29 Feb, 2024

Updated 31 Oct, 2024

Last price

Market cap $B

0.06

Micro

Exchange

OOTC - OTC

BIOQ Stock Analysis

BI

Avoid

Based on Eyestock quantitative analysis, BIOQ`s fundamental data and valuation indicate an investment grade of Avoid at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

59/100

Moderate score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

-79.9 %

Greatly overvalued

Market cap $B

0.06

Dividend yield

Shares outstanding

0.894 B

Bioqual, Inc. engages in the provision and development of medical research and consulting services to commercial clients and government laboratories. The company is headquartered in Rockville, Maryland. The company is involved in the evaluation of vaccines, vaccine therapeutics, microbicides, and drug therapies. The firm also performs in vitro contract research services. The in vitro services include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation and other cell-based assays. The company also provides research services in herpes simplex in rodents, filariasis in rhesus macaques, chikungunya in rodents and macaques and dengue in rodents and macaques.

View Section: Eyestock Rating